Pacira Pharmaceuticals Stock Performance
| PCRX Stock | USD 25.90 0.91 3.39% |
The company holds a Beta of 0.88, which implies possible diversification benefits within a given portfolio. Pacira Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Pacira Pharmaceuticals is expected to follow. Pacira Pharmaceuticals has an expected return of -0.28%. Please make sure to check Pacira Pharmaceuticals maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Pacira Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pacira Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.21) | Five Day Return (0.12) | Year To Date Return (18.91) | Ten Year Return (61.71) | All Time Return 269.66 |
1 | Pacira BioSciences, Inc. Q4 2023 Earnings Call Transcript | 03/01/2024 |
2 | Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference | 03/06/2024 |
3 | JPMorgan sets 45 target on Pacira stock with Overweight rating | 03/07/2024 |
4 | Disposition of 90000 shares by Gary Pace of Pacira Pharmaceuticals at 30.6 subject to Rule 16b-3 | 03/08/2024 |
5 | Paciras gene therapy gets FDAs first osteoarthritis RMAT nod | 03/13/2024 |
6 | Disposition of 2267 shares by Molloy Anthony of Pacira Pharmaceuticals at 38.277 subject to Rule 16b-3 | 03/20/2024 |
7 | Global Local Anesthesia Drugs Market Forecast Reveals High Demand and Expansion by 2029 | 03/26/2024 |
8 | Acquisition by Bigal Marcelo of 30967 shares of Pacira Pharmaceuticals at 29.8 subject to Rule 16b-3 | 04/01/2024 |
9 | Paciras Q4 Earnings Top Estimates, Revenues In Line - Yahoo Movies UK | 04/10/2024 |
| Begin Period Cash Flow | 104.1 M |
Pacira |
Pacira Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,239 in Pacira Pharmaceuticals on January 25, 2024 and sell it today you would lose (558.00) from holding Pacira Pharmaceuticals or give up 17.23% of portfolio value over 90 days. Pacira Pharmaceuticals is currently does not generate positive expected returns and assumes 2.0954% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Pacira, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pacira Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pacira Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pacira Pharmaceuticals, and traders can use it to determine the average amount a Pacira Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1326
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCRX |
Estimated Market Risk
| 2.1 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pacira Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pacira Pharmaceuticals by adding Pacira Pharmaceuticals to a well-diversified portfolio.
Pacira Pharmaceuticals Fundamentals Growth
Pacira Stock prices reflect investors' perceptions of the future prospects and financial health of Pacira Pharmaceuticals, and Pacira Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pacira Stock performance.
| Return On Equity | 0.051 | ||||
| Return On Asset | 0.0335 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 1.52 B | ||||
| Shares Outstanding | 46.52 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 674.98 M | ||||
| Gross Profit | 393.23 M | ||||
| EBITDA | 162.9 M | ||||
| Net Income | 41.95 M | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 586.04 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 18.72 X | ||||
| Cash Flow From Operations | 154.65 M | ||||
| Earnings Per Share | 0.89 X | ||||
| Market Capitalization | 1.25 B | ||||
| Total Asset | 1.57 B | ||||
| Retained Earnings | (106.8 M) | ||||
| Working Capital | 412.61 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
About Pacira Pharmaceuticals Performance
To evaluate Pacira Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Pacira Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Pacira Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Pacira Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Pacira's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 157.42 | 116.53 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
Things to note about Pacira Pharmaceuticals performance evaluation
Checking the ongoing alerts about Pacira Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pacira Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pacira Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pacira Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Paciras Q4 Earnings Top Estimates, Revenues In Line - Yahoo Movies UK |
- Analyzing Pacira Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pacira Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Pacira Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pacira Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pacira Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pacira Pharmaceuticals' stock. These opinions can provide insight into Pacira Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.